Community-acquired pneumonia (CAP) is described as an acute infection of the lung parenchyma acquired in the community. It is most commonly bacterial in nature and is associated with clinical and/or radiological evidence of consolidation of part or parts of one or both lungs. The most commonly identified pathogens are Streptococcus pneumoniae, Haemophilus influenzae, a typical bacteria (i.e., Chlamydia pneumoniae, Mycoplasma pneumoniae, Legionella sp).
Many studies have suggested that the incidence of CAP is slightly higher in males as compared to females.
DelveInsight’s ‘Community-Acquired Bacterial Pneumonia (CABP) – Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Community-Acquired Bacterial Pneumonia (CABP) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Geographies Covered
Study Period: 2017-2030
Download sample pages: https://www.delveinsight.com/sample-request/community-acquired-bacterial-pneumonia-cabp-epidemiology-forecast
Community-Acquired Bacterial Pneumonia (CABP) Understanding
The DelveInsight Community-Acquired Bacterial Pneumonia (CABP) epidemiology report gives a thorough understanding of the Community-Acquired Bacterial Pneumonia (CABP) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Community-Acquired Bacterial Pneumonia (CABP) in the US, Europe, and Japan. The report covers the detailed information of the Community-Acquired Bacterial Pneumonia (CABP) epidemiology scenario in seven major countries (US, EU5, and Japan).
Community-Acquired Bacterial Pneumonia (CABP) Epidemiology Perspective by DelveInsight
The Community-Acquired Bacterial Pneumonia (CABP) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Community-Acquired Bacterial Pneumonia (CABP) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Community-Acquired Bacterial Pneumonia (CABP) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Community-Acquired Bacterial Pneumonia (CABP) Detailed Epidemiology Segmentation
The Community-Acquired Bacterial Pneumonia (CABP) epidemiology covered in the report provides historical as well as forecasted Community-Acquired Bacterial Pneumonia (CABP) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
The DelveInsight Community-Acquired Bacterial Pneumonia (CABP) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
Request for sample pages: https://www.delveinsight.com/sample-request/community-acquired-bacterial-pneumonia-cabp-epidemiology-forecast
Scope of the Report
Report Highlights
Table of contents:
1. Key Insights
2. Executive Summary of Community-Acquired Bacterial Pneumonia (CABP)
3. Community-Acquired Bacterial Pneumonia (CABP): Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Community-Acquired Bacterial Pneumonia (CABP) Epidemiology Scenario in the 7MM (2017- 2030)
5.4. United States Epidemiology
5.4.1. Community-Acquired Bacterial Pneumonia (CABP) Epidemiology Scenario in the United States (2017- 2030)
5.5. EU-5 Country-wise Epidemiology
5.6. Japan Epidemiology
5.6.1. Community-Acquired Bacterial Pneumonia (CABP) Epidemiology Scenario in Japan (2017- 2030)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Community-Acquired Bacterial Pneumonia (CABP) Treatment and Management
6.2. Community-Acquired Bacterial Pneumonia (CABP) Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
*The table of contents is not exhaustive; will be provided in the final report.
Download report: https://www.delveinsight.com/sample-request/community-acquired-bacterial-pneumonia-cabp-epidemiology-forecast
About DelveInsightDelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:Shruti Thakur[email protected]+919650213330
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/